Immutep Limited (IMM.AX)
AUD 0.23
(-6.12%)
AUD 0.23
(-6.12%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -39.89 Million AUD | -23.86% |
| 2021 | -32.21 Million AUD | -7.72% |
| 2020 | -29.9 Million AUD | -122.02% |
| 2019 | -13.46 Million AUD | 17.22% |
| 2018 | -16.27 Million AUD | -27.65% |
| 2017 | -12.74 Million AUD | -36.07% |
| 2016 | -9.36 Million AUD | 84.9% |
| 2015 | -62.01 Million AUD | -92.88% |
| 2014 | -32.15 Million AUD | -140.96% |
| 2013 | -13.34 Million AUD | 12.36% |
| 2012 | -15.22 Million AUD | 23.65% |
| 2011 | -19.94 Million AUD | 5.41% |
| 2010 | -21.08 Million AUD | -73.38% |
| 2009 | -12.15 Million AUD | -312.67% |
| 2008 | -2.94 Million AUD | -56.11% |
| 2007 | -1.88 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 Q2 | -20.62 Million AUD | 0.0% |
| 2022 Q4 | -19.27 Million AUD | 0.0% |
| 2022 FY | -39.89 Million AUD | -23.86% |
| 2021 FY | -32.21 Million AUD | -7.72% |
| 2021 Q2 | -16.27 Million AUD | 0.0% |
| 2021 Q4 | -15.94 Million AUD | 0.0% |
| 2020 FY | -29.9 Million AUD | -122.02% |
| 2020 Q4 | -10.05 Million AUD | 0.0% |
| 2020 Q2 | -19.84 Million AUD | 0.0% |
| 2019 Q2 | -5.95 Million AUD | 0.0% |
| 2019 FY | -13.46 Million AUD | 17.22% |
| 2019 Q4 | -7.51 Million AUD | 0.0% |
| 2018 Q4 | -9.66 Million AUD | 0.0% |
| 2018 Q2 | -8.67 Million AUD | 0.0% |
| 2018 FY | -16.27 Million AUD | -27.65% |
| 2017 FY | -12.74 Million AUD | -36.07% |
| 2017 Q4 | -8.42 Million AUD | 0.0% |
| 2017 Q2 | -4.32 Million AUD | 0.0% |
| 2016 Q3 | -2.22 Million AUD | 45.13% |
| 2016 Q4 | -3.07 Million AUD | -37.95% |
| 2016 FY | -9.36 Million AUD | 84.9% |
| 2016 Q2 | -4.06 Million AUD | 0.0% |
| 2015 FY | -62.01 Million AUD | -92.88% |
| 2015 Q4 | -3.51 Million AUD | -42.18% |
| 2015 Q3 | -2.47 Million AUD | 95.58% |
| 2015 Q2 | -56.02 Million AUD | 0.0% |
| 2014 Q2 | -6.4 Million AUD | 0.0% |
| 2014 FY | -32.15 Million AUD | -140.96% |
| 2014 Q4 | -25.75 Million AUD | 0.0% |
| 2013 Q2 | -5.95 Million AUD | 0.0% |
| 2013 FY | -13.34 Million AUD | 12.36% |
| 2013 Q4 | -7.38 Million AUD | 0.0% |
| 2012 FY | -15.22 Million AUD | 23.65% |
| 2012 Q4 | -7.19 Million AUD | 0.0% |
| 2012 Q2 | -8.03 Million AUD | 0.0% |
| 2011 FY | -19.94 Million AUD | 5.41% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | -21.08 Million AUD | -73.38% |
| 2009 FY | -12.15 Million AUD | -312.67% |
| 2008 FY | -2.94 Million AUD | -56.11% |
| 2007 FY | -1.88 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -641.393% |
| Acrux Limited | -5.8 Million AUD | -587.868% |
| Race Oncology Limited | -13.81 Million AUD | -188.699% |
| Biome Australia Limited | -1.67 Million AUD | -2288.714% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | -187.651% |
| BTC Health Limited | 1.05 Million AUD | 3880.616% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | -218.41% |
| CSL Limited | 2.64 Billion AUD | 101.51% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 5.737% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 211.954% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 672.854% |
| Hexima Limited | -933.87 Thousand AUD | -4172.139% |
| Memphasys Limited | -4.44 Million AUD | -798.158% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 125.399% |
| Noxopharm Limited | -3.57 Million AUD | -1015.01% |
| Prescient Therapeutics Limited | -8.23 Million AUD | -384.294% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 16.794% |
| Starpharma Holdings Limited | -8.16 Million AUD | -388.626% |
| Tissue Repair Ltd | -4.13 Million AUD | -864.121% |
| Biotron Limited | -3.43 Million AUD | -1060.951% |
| Alterity Therapeutics Limited | -19.12 Million AUD | -108.625% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -2649.118% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -1556.014% |
| Zelira Therapeutics Limited | -36.56 Million AUD | -9.099% |
| Patrys Limited | -3.53 Million AUD | -1027.286% |
| Orthocell Limited | -7.18 Million AUD | -455.585% |
| Imugene Limited | -149.68 Million AUD | 73.346% |
| PYC Therapeutics Limited | -37.72 Million AUD | -5.755% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -525.705% |
| Cynata Therapeutics Limited | -9.74 Million AUD | -309.415% |
| Arovella Therapeutics Limited | -8.74 Million AUD | -356.165% |
| Nanollose Limited | -1.15 Million AUD | -3349.591% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -2330.024% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 12405.712% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -785.906% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -1292.874% |
| Nyrada Inc. | -1.38 Million AUD | -2778.053% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 865.618% |
| Dimerix Limited | -17.07 Million AUD | -133.652% |
| PharmAust Limited | -9.03 Million AUD | -341.705% |
| AnteoTech Limited | -8.88 Million AUD | -349.257% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 31.979% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | -125.892% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -1060.938% |
| Actinogen Medical Limited | -13.04 Million AUD | -205.853% |
| Immuron Limited | -6.93 Million AUD | -475.128% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -628.104% |